vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Navitas Semiconductor Corp (NVTS). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $8.6M, roughly 1.7× Navitas Semiconductor Corp). On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -38.7%). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -35.2%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Navitas Semiconductor Corp is a leading global semiconductor firm specializing in gallium nitride (GaN) power integrated circuits. Its high-efficiency, compact power solutions serve consumer electronics, electric vehicles, renewable energy, and industrial sectors, with clients spanning North America, Asia, and Europe.
CSBR vs NVTS — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $8.6M |
| Net Profit | $268.0K | — |
| Gross Margin | 51.7% | 98.6% |
| Operating Margin | 1.2% | -260.6% |
| Net Margin | 1.8% | — |
| Revenue YoY | 11.5% | -38.7% |
| Net Profit YoY | -63.2% | — |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $8.6M | ||
| Q4 25 | $15.0M | $7.3M | ||
| Q3 25 | $14.0M | $10.1M | ||
| Q2 25 | $12.4M | $14.5M | ||
| Q1 25 | $17.0M | $14.0M | ||
| Q4 24 | $13.5M | $18.0M | ||
| Q3 24 | $14.1M | $21.7M | ||
| Q2 24 | $14.0M | $20.5M |
| Q1 26 | — | — | ||
| Q4 25 | $268.0K | $-31.8M | ||
| Q3 25 | $-436.0K | $-19.2M | ||
| Q2 25 | $-1.8M | $-49.1M | ||
| Q1 25 | $4.5M | $-16.8M | ||
| Q4 24 | $728.0K | $-39.9M | ||
| Q3 24 | $1.3M | $-18.7M | ||
| Q2 24 | $-109.0K | $-22.3M |
| Q1 26 | — | 98.6% | ||
| Q4 25 | 51.7% | 38.1% | ||
| Q3 25 | 42.9% | 37.9% | ||
| Q2 25 | 41.1% | 16.1% | ||
| Q1 25 | 61.2% | 37.9% | ||
| Q4 24 | 44.9% | 12.4% | ||
| Q3 24 | 49.7% | 39.7% | ||
| Q2 24 | 48.2% | 39.0% |
| Q1 26 | — | -260.6% | ||
| Q4 25 | 1.2% | -567.3% | ||
| Q3 25 | -3.8% | -192.0% | ||
| Q2 25 | -16.2% | -149.4% | ||
| Q1 25 | 26.4% | -180.5% | ||
| Q4 24 | 5.4% | -216.9% | ||
| Q3 24 | 9.5% | -133.6% | ||
| Q2 24 | -1.9% | -152.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | -436.1% | ||
| Q3 25 | -3.1% | -190.2% | ||
| Q2 25 | -14.9% | -338.7% | ||
| Q1 25 | 26.4% | -120.1% | ||
| Q4 24 | 5.4% | -221.7% | ||
| Q3 24 | 9.3% | -86.4% | ||
| Q2 24 | -0.8% | -109.1% |
| Q1 26 | — | — | ||
| Q4 25 | $0.02 | $-0.14 | ||
| Q3 25 | $-0.03 | $-0.09 | ||
| Q2 25 | $-0.12 | $-0.25 | ||
| Q1 25 | $0.31 | $-0.09 | ||
| Q4 24 | $0.05 | $-0.22 | ||
| Q3 24 | $0.09 | $-0.10 | ||
| Q2 24 | $-0.01 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $221.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $420.0M |
| Total Assets | $30.2M | $481.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $221.0M | ||
| Q4 25 | $8.5M | $236.9M | ||
| Q3 25 | $10.3M | $150.6M | ||
| Q2 25 | $9.8M | $161.2M | ||
| Q1 25 | $3.2M | $75.1M | ||
| Q4 24 | $2.8M | $86.7M | ||
| Q3 24 | $2.9M | $98.3M | ||
| Q2 24 | $2.6M | $111.7M |
| Q1 26 | — | $420.0M | ||
| Q4 25 | $4.2M | $443.7M | ||
| Q3 25 | $3.5M | $371.0M | ||
| Q2 25 | $3.8M | $388.9M | ||
| Q1 25 | $5.5M | $341.8M | ||
| Q4 24 | $681.0K | $348.0M | ||
| Q3 24 | $-332.0K | $380.8M | ||
| Q2 24 | $-1.9M | $388.1M |
| Q1 26 | — | $481.4M | ||
| Q4 25 | $30.2M | $500.5M | ||
| Q3 25 | $30.5M | $430.2M | ||
| Q2 25 | $32.3M | $449.4M | ||
| Q1 25 | $30.6M | $370.8M | ||
| Q4 24 | $25.2M | $390.0M | ||
| Q3 24 | $24.9M | $419.4M | ||
| Q2 24 | $26.1M | $439.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | — |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-1.7M | $-8.1M | ||
| Q3 25 | $600.0K | $-10.0M | ||
| Q2 25 | $6.9M | $-11.2M | ||
| Q1 25 | $490.0K | $-13.5M | ||
| Q4 24 | $-283.0K | $-10.2M | ||
| Q3 24 | $311.0K | $-13.7M | ||
| Q2 24 | $-1.8M | $-15.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-2.0M | $-8.2M | ||
| Q3 25 | $554.0K | $-10.7M | ||
| Q2 25 | $6.6M | $-11.9M | ||
| Q1 25 | $448.0K | $-13.6M | ||
| Q4 24 | $-377.0K | $-10.8M | ||
| Q3 24 | — | $-14.3M | ||
| Q2 24 | $-1.8M | $-17.9M |
| Q1 26 | — | — | ||
| Q4 25 | -13.1% | -111.8% | ||
| Q3 25 | 4.0% | -106.1% | ||
| Q2 25 | 53.5% | -82.2% | ||
| Q1 25 | 2.6% | -96.8% | ||
| Q4 24 | -2.8% | -59.8% | ||
| Q3 24 | — | -65.9% | ||
| Q2 24 | -13.0% | -87.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 0.7% | ||
| Q3 25 | 0.3% | 7.0% | ||
| Q2 25 | 2.0% | 4.7% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.7% | 3.1% | ||
| Q3 24 | 0.0% | 2.6% | ||
| Q2 24 | 0.0% | 13.4% |
| Q1 26 | — | — | ||
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
NVTS
Segment breakdown not available.
